CellaVision Financial Statements From 2010 to 2025
| CLVSF Stock | USD 16.83 3.41 16.85% |
Check CellaVision financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CellaVision's main balance sheet or income statement drivers, such as , as well as many indicators such as . CellaVision financial statements analysis is a perfect complement when working with CellaVision Valuation or Volatility modules.
CellaVision |
CellaVision AB Company Current Valuation Analysis
CellaVision's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current CellaVision Current Valuation | 600.98 M |
Most of CellaVision's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CellaVision AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, CellaVision AB has a Current Valuation of 600.98 M. This is 95.82% lower than that of the Healthcare sector and 95.16% lower than that of the Medical Devices industry. The current valuation for all United States stocks is 96.38% higher than that of the company.
CellaVision AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining CellaVision's current stock value. Our valuation model uses many indicators to compare CellaVision value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CellaVision competition to find correlations between indicators driving CellaVision's intrinsic value. More Info.CellaVision AB is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.58 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for CellaVision AB is roughly 1.73 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CellaVision's earnings, one of the primary drivers of an investment's value.About CellaVision Financial Statements
CellaVision stakeholders use historical fundamental indicators, such as CellaVision's revenue or net income, to determine how well the company is positioned to perform in the future. Although CellaVision investors may analyze each financial statement separately, they are all interrelated. For example, changes in CellaVision's assets and liabilities are reflected in the revenues and expenses on CellaVision's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in CellaVision AB. Please read more on our technical analysis and fundamental analysis pages.
CellaVision AB develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific. CellaVision AB was incorporated in 1994 and is headquartered in Lund, Sweden. Cellavision is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in CellaVision Pink Sheet
CellaVision financial ratios help investors to determine whether CellaVision Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CellaVision with respect to the benefits of owning CellaVision security.